AbbVie preps a challenge to a rival migraine drug from Biohaven, spelling out an upbeat set of PhIII data
Phase III advance trial data for AbbVie’s migraine prevention drug atogepant look good — but are the results good enough to rival Biohaven’s two-in-one treatment and prevention drug, rimegepant, sold as Nurtec?
AbbVie picked up atogepant from Allergan in a $63 billion buyout last year. It also claimed the Botox franchise and $16 billion in annual revenue.
Vamil Divan, an equity research analyst with Mizuho Financial Group, said atogepant and rimegepant are “natural competitors”: two oral drugs that could hit the market around the same time. Nurtec took the lead with FDA approval in February. Atogepant met primary and secondary endpoints in pivotal Phase III testing, and Illinois-based AbbVie is pushing for regulatory submissions in the US and abroad.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.